Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
Journal: The New England journal of medicine
Published: June 23, 2025
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Journal: The New England journal of medicine
Published: April 24, 2024
Use of Identical INN "Imiglucerase" for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database.
Journal: Drug safety
Published: September 21, 2021
How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations.
Journal: Molecular genetics and metabolism
Published: July 08, 2020
Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1.
Journal: Molecular genetics and metabolism reports
Published: December 17, 2019
Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents.
Journal: Molecular genetics and metabolism
Published: July 24, 2019
Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
Journal: Lancet (London, England)
Published: March 31, 2015
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Journal: Blood cells, molecules & diseases
Published: March 03, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026